Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07091695 · ClinicalTrials.gov registry record
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 100
- Enrollment target
NCT07091695 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 100 participants.
The verdict
NCT07091695 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the real-world use of neoadjuvant nivolumab+relatlimab or nivolumab+ipilimumab
Interventions
- BIOLOGICAL Nivolumab + ipilimumab
- BIOLOGICAL Nivolumab + relatlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-11 |
| Est. Completion | 2025-11-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07091695
The ClinicalTrials.gov registry entry for NCT07091695 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab + ipilimumab is the first listed.
NCT07091695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07091695 about?
NCT07091695 is a clinical study titled "Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab". The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the real-world use of neoadjuvant nivolumab+relatlimab or nivolumab+ipilim...
What is the current status of trial NCT07091695?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2025-05-11. Estimated completion is 2025-11-06.
What interventions are being tested in trial NCT07091695?
The interventions under investigation include: Nivolumab + ipilimumab (BIOLOGICAL), Nivolumab + relatlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT07091695?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.